Stock Earnings
EYPT stock rated a Buy by Citigroup
EyePoint Pharmaceuticals Inc’s filing revealed that its Director Zaderej Karen L. acquired Company’s shares for reported $27350.0 on May 15
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.